2022
Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
Yu Y, Guan W, Masoudi FA, Wang B, He G, Spertus JA, Lu Y, Krumholz HM, Li J. Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study. Journal Of The American Heart Association 2022, 11: e026300. PMID: 36172964, PMCID: PMC9673705, DOI: 10.1161/jaha.122.026300.Peer-Reviewed Original ResearchConceptsSpironolactone prescriptionSpironolactone useHeart failureMedian odds ratioIdeal patientAldosterone antagonistsHospital variationMedian rateReduced ejection fractionUse of spironolactoneMultivariable linear regression modelsHeart Failure StudyEjection fractionHospital characteristicsOdds ratioRepresentative cohortPatientsHospitalChinese hospitalsInappropriate usePrescriptionSpironolactoneSelect individualsAntagonistHigh rate
2015
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011
Guan W, Murugiah K, Downing N, Li J, Wang Q, Ross JS, Desai NR, Masoudi FA, Spertus JA, Li X, Krumholz HM, Jiang L, Group T. National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Journal Of The American Heart Association 2015, 4: e001718. PMID: 26071031, PMCID: PMC4599529, DOI: 10.1161/jaha.114.001718.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionHeart failureMyocardial infarctionUse of spironolactoneNational practice patternsProportion of patientsAssessment of eligibilitySpironolactone useAldosterone antagonistsSystolic dysfunctionCardiac eventsAMI patientsChina PatientPatient eligibilityPatient groupUnknown indicationPractice patternsIdeal patientPatientsSpironolactoneEligibilityAppropriate useInfarctionDiabetesNational quality assessment
2005
Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001. Circulation 2005, 112: 39-47. PMID: 15983243, DOI: 10.1161/circulationaha.104.527549.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCohort StudiesCreatinineDiureticsDrug PrescriptionsFemaleFollow-Up StudiesHeart FailureHumansMaleMineralocorticoid Receptor AntagonistsPatient SelectionPotassiumRandomized Controlled Trials as TopicRisk AssessmentSpironolactoneUnited StatesVentricular Dysfunction, LeftConceptsRandomized Aldactone Evaluation StudyPublication of RALESVentricular systolic dysfunctionHeart failureEnrollment criteriaSpironolactone prescriptionSpironolactone therapySystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionPatients meeting enrollment criteriaSerial cross-sectional samplesSevere renal dysfunctionSerum creatinine valuesAldactone Evaluation StudyMultivariable logistic regressionSerum potassium valuesSkilled nursing facilitiesNoncardiovascular comorbiditiesSpironolactone useRenal dysfunctionAdverse eventsHospital dischargeAppropriate patientsMultivariable analysis
2004
Prognostic Value of Health Status in Patients With Heart Failure After Acute Myocardial Infarction
Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic Value of Health Status in Patients With Heart Failure After Acute Myocardial Infarction. Circulation 2004, 110: 546-551. PMID: 15262843, DOI: 10.1161/01.cir.0000136991.85540.a9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmericasCardiovascular DiseasesCohort StudiesComorbidityDisease-Free SurvivalEplerenoneEuropeFemaleHealth Status IndicatorsHeart FailureHospitalizationHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsMyocardial InfarctionPrognosisProspective StudiesRisk FactorsSeverity of Illness IndexSpironolactoneConceptsKansas City Cardiomyopathy QuestionnaireAcute myocardial infarctionHeart failureKCCQ-OSMyocardial infarctionHealth statusKCCQ scoresCardiovascular mortalityPrognostic valueDisease-specific health status instrumentRecent acute myocardial infarctionSubsequent cardiovascular eventsEvent-free survivalOutpatient clinical practiceFirst outpatient visitHealth status instrumentsPatients' health statusQuality of lifeCardiovascular eventsClinical characteristicsOutpatient visitsMultivariable modelInternational cohortFunctional limitationsClinical practice
2003
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure
Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. American Heart Journal 2003, 146: 250-257. PMID: 12891192, DOI: 10.1016/s0002-8703(03)00189-3.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCross-Sectional StudiesFemaleHeart FailureHospitalizationHumansMaleMineralocorticoid Receptor AntagonistsPatient SelectionRandomized Controlled Trials as TopicSpironolactoneUnited StatesVentricular Dysfunction, LeftConceptsLeft ventricular systolic functionVentricular systolic functionHeart failureEnrollment criteriaClinical trialsOlder personsSystolic functionRandomized Aldactone Evaluation Study (RALES) trialHospitalized older personsRandomized Intervention TrialTrials of agentsLeft ventricular dysfunctionCongestive heart failureHeart failure patientsAcute care hospitalsCross-sectional studySubgroups of ageCommunity-based practiceTrial eligibilityVentricular dysfunctionFailure patientsOlder patientsCare hospitalMERIT-HFTrial population